Lataa...
Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?
Alzheimer's disease (AD) drug developments and clinical trials (CT) remain vulnerable to problems that undermine research validity. Investigations of CT methods reveal how numerous factors decrease active drug-placebo group differences and increase variance, thereby reducing power to reach stat...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2008
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3372084/ https://ncbi.nlm.nih.gov/pubmed/18953116 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|